The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
HYMPAVZI’s safety profile was generally favorable
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
MRI is particularly valuable in pediatric care due to its non-invasive nature
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Subscribe To Our Newsletter & Stay Updated
